Core Viewpoint - Sinovac Biotech Ltd. faces delisting from NASDAQ due to failure to submit its 2024 annual report by the extended deadline of November 11, 2025, with plans to appeal the decision [1][2] Group 1: Company Background - Sinovac Biotech was founded in 2001 by Yin Weidong and Pan Aihua, focusing on the research, development, production, and sales of human vaccines [2] - The company went public in the U.S. through a reverse acquisition in 2003 and has since transitioned to NASDAQ [2] Group 2: Control Struggles - The control struggle began in 2016 when the company planned to privatize and return to mainland China, leading to a split between Yin Weidong and Pan Aihua over management [3] - The conflict escalated with extreme actions, including seizing company seals and production facilities, resulting in temporary vaccine production halts [3] - In 2025, the UK Privy Council's ruling led to the replacement of four board members, intensifying the control dispute [3][4] Group 3: Financial Implications - Sinovac announced significant dividend payouts in 2025, including $55 per share and additional special dividends, which are seen as attempts to stabilize shareholder confidence amid ongoing disputes [4] - High dividend payments may limit funds available for R&D and operational expansion, potentially affecting the company's long-term growth [5] - The company's sales peaked at $19.4 billion in 2021 due to the approval of its COVID-19 vaccine, but recent reports indicate a decline in sales to $121.3 million in the first half of 2024, a 13.6% decrease year-over-year [5]
科兴生物收到纳斯达克退市通知，最新回应